Chronic immune thrombocytopenia nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia

Haiyu Zhang, Bing M. Zhang, Xiangqian Guo, Liwen Xu, Xiaoqing You, Robert B. West, James B. Bussel, and James L. Zehnder

Disclosures: JBB has been a consultant for GlaxoSmithKline and Novartis; received research funding from Amgen, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Prophylux Pharma, Protalex, Rigel Pharmaceuticals; participated in advisory boards for Amgen, Momenta Pharmaceuticals, Novartis, Prophylux Pharma, Protalex, Rigel Pharmaceuticals, Dova, UCB, Argenx, and RallyBio; has received a royalty from UpToDate, and participated in a speakers bureau for Novartis and Physicians Education Resource. JLZ has been a consultant for Novartis, received research funding from GlaxoSmithKline and royalties form UpToDate. Other authors declare no competing financial interests.

Contributions: All authors meet the criteria for authorship according to the International Committee of Medical Journal Editors guidelines. BMZ, HZ, JBB, and JLZ contributed to the study concept and design, HZ, LX, and BMZ contributed to the acquisition of the data, XG, HZ, XY, BMZ, RBW, and JBB contributed to analysis of the data, HZ, BMZ, JBB, and JLZ contributed to interpretation of the data and drafted the manuscript. All authors provided critical review of the manuscript and approval of the final version of the manuscript.